Literature DB >> 20171865

The Global Fund's leadership on harm reduction: 2002-2009.

Rifat Atun1, Michel Kazatchkine.   

Abstract

Injecting drug use is a major driver of the HIV epidemic globally. Whilst robust evidence points to the effectiveness of harm reduction programmes to halt and reverse injecting drug use driven epidemics, uptake of these programmes in developing and transitional countries has been slow. In part, this slow uptake stems from inadequate financial resources for harm reduction; legal, socio-cultural and medical barriers leading to stigmatisation; and weak health systems unequipped to manage marginalized groups. The Global Fund to Fight AIDS, Tuberculosis and Malaria, established in 2002, has become the major multilateral source of external funding for harm reduction programmes in countries experiencing concentrated HIV epidemics driven by injecting drug use. Between 2004 to end of 2008, the Global Fund invested around US$180 million in harm reduction programmes in 42 countries. This funding has helped to initiate and scale up harm reduction programmes in settings where domestic funding was lacking. In addition to financing harm reduction programmes globally, the Global Fund has stimulated a strong dialogue between vulnerable groups and governments. Furthermore, the Global Fund has engaged in a dialogue with countries to encourage an evidence-based approach to policy-making that recognizes the immense value of harm reduction in HIV prevention and control. Copyright (c) 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20171865     DOI: 10.1016/j.drugpo.2010.01.002

Source DB:  PubMed          Journal:  Int J Drug Policy        ISSN: 0955-3959


  3 in total

Review 1.  Public health and international drug policy.

Authors:  Joanne Csete; Adeeba Kamarulzaman; Michel Kazatchkine; Frederick Altice; Marek Balicki; Julia Buxton; Javier Cepeda; Megan Comfort; Eric Goosby; João Goulão; Carl Hart; Thomas Kerr; Alejandro Madrazo Lajous; Stephen Lewis; Natasha Martin; Daniel Mejía; Adriana Camacho; David Mathieson; Isidore Obot; Adeolu Ogunrombi; Susan Sherman; Jack Stone; Nandini Vallath; Peter Vickerman; Tomáš Zábranský; Chris Beyrer
Journal:  Lancet       Date:  2016-03-24       Impact factor: 79.321

2.  Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine.

Authors:  Sung Wook Kim; Anni-Maria Pulkki-Brannstrom; Jolene Skordis-Worrall
Journal:  Cost Eff Resour Alloc       Date:  2014-11-24

3.  Human Rights and the Global Fund to Fight AIDS, Tuberculosis and Malaria: How Does a Large Funder of Basic Health Services Meet the Challenge of Rights-Based Programs?

Authors:  Ralf Jürgens; Joanne Csete; Hyeyoung Lim; Susan Timberlake; Matthew Smith
Journal:  Health Hum Rights       Date:  2017-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.